4D Molecular Therapeutics, Inc. (FDMT): R&D Expense
$195.70M
Year ended 2025-12-31
$240.31M
Trailing 12 months to 2026-06-30
+34.6%
3-year compound annual growth
+29.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $195.70M | +38.5% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $141.30M | +45.5% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $97.10M | +21.0% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $80.25M | +30.8% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $61.36M | +15.7% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $53.04M | +37.0% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $38.72M | n/a | 2021-03-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $195.70M | +38.5% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $129.62M | +8.5% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $117.69M | -15.0% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $475.27M | +51.2% |
| Compugen Ltd (CGEN) | 2025-12-31 | $22.76M | -8.3% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $33.56M | -34.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $455.97M | -10.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
Compare FDMT, MGTX, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗